Veeva Systems Inc. $VEEV Shares Sold by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co trimmed its holdings in Veeva Systems Inc. (NYSE:VEEV) by 50.0% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,000 shares of the technology company’s stock after selling 1,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Veeva Systems were worth $288,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. TFB Advisors LLC grew its stake in shares of Veeva Systems by 1.2% in the first quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock worth $831,000 after purchasing an additional 44 shares in the last quarter. Triangle Securities Wealth Management raised its holdings in Veeva Systems by 0.8% during the second quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock worth $1,665,000 after purchasing an additional 45 shares in the last quarter. Marks Group Wealth Management Inc lifted its position in Veeva Systems by 3.3% in the first quarter. Marks Group Wealth Management Inc now owns 1,427 shares of the technology company’s stock worth $331,000 after purchasing an additional 46 shares during the period. Harbour Investments Inc. boosted its stake in Veeva Systems by 7.6% during the 1st quarter. Harbour Investments Inc. now owns 789 shares of the technology company’s stock valued at $183,000 after purchasing an additional 56 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in Veeva Systems by 4.7% during the 2nd quarter. Parallel Advisors LLC now owns 1,236 shares of the technology company’s stock valued at $356,000 after purchasing an additional 56 shares in the last quarter. Institutional investors own 88.20% of the company’s stock.

Veeva Systems Price Performance

Shares of VEEV opened at $293.11 on Friday. Veeva Systems Inc. has a one year low of $201.54 and a one year high of $310.50. The company has a 50-day moving average of $284.70 and a two-hundred day moving average of $269.66. The stock has a market cap of $48.04 billion, a price-to-earnings ratio of 60.19, a PEG ratio of 2.27 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.90 by ($0.64). Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The firm had revenue of $789.08 million during the quarter, compared to analysts’ expectations of $768.49 million. During the same quarter last year, the company posted $1.62 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Truist Financial upped their price objective on Veeva Systems from $268.00 to $275.00 and gave the company a “hold” rating in a report on Thursday, August 28th. Mizuho upped their price target on shares of Veeva Systems from $295.00 to $325.00 and gave the company an “outperform” rating in a report on Friday, August 29th. Citigroup raised their price objective on shares of Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Needham & Company LLC reiterated a “buy” rating and issued a $355.00 target price on shares of Veeva Systems in a report on Friday, October 17th. Finally, Canaccord Genuity Group increased their target price on shares of Veeva Systems from $270.00 to $300.00 and gave the company a “hold” rating in a research note on Thursday, August 28th. Seventeen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.58.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 3,350 shares of Veeva Systems stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the transaction, the insider owned 23,773 shares in the company, valued at approximately $7,132,850.92. The trade was a 12.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jonathan Faddis sold 720 shares of the company’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $298.12, for a total value of $214,646.40. Following the transaction, the senior vice president directly owned 7,868 shares in the company, valued at $2,345,608.16. The trade was a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,665 shares of company stock valued at $7,438,000 over the last quarter. Company insiders own 10.30% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.